Pneumococcal vaccine

Speaking of pneumococcus, some of you may not know the seriousness of this pathogen and think that there is no need for targeted vaccination against it. In fact, what you don’t know is that pneumococcus is an important pathogen that causes death in children today, especially for infants and young children. The number of deaths due to pneumococcus is increasing year by year. Therefore, in order to avoid pneumococcus from causing harm to your baby, please be sure to give your baby the pneumococcal vaccine in time.

However, I need to explain to you that although the pneumococcal vaccine can prevent pneumococcus, it can only resist several types of pneumococcus. Even for babies under 2 years old, the pneumococcal vaccine has no resistance effect. This shows the harm of pneumococcus.

There are many types of pneumonia, and pneumococcus is the main pathogen of pneumonia. Worldwide, 5-10% of healthy adults and 20-40% of healthy children are carriers of pneumococci. Pneumococcus generally lives in the nasopharynx of normal people and generally does not cause disease. However, when the body's immunity is reduced, such as due to colds, fatigue, chronic bronchitis, chronic heart disease, long-term smoking, etc., pneumococcus can take advantage of the situation and invade, causing various diseases.

The purified pneumococcal capsular polysaccharides contained in the pneumococcal vaccine can induce the production of antibodies, which can effectively prevent pneumococcal infection. Human studies using multivalent vaccines have shown that they can confers immunity to each of the 23 capsular types. Adults of any age can develop an immune response to vaccines. During the third week after vaccination, levels of protective capsule-type-specific antibodies will increase.

The duration of the protective effect of Pneumofacitin 23 has not yet been determined, but earlier studies have shown that antibodies stimulated by other pneumococcal vaccines can last for up to 5 years. The level of specific antibodies stimulated by Nimofa decreased after 42 months of observation, but was still significantly higher than the pre-vaccination level in all subjects with signs of early response. Used for immunization against diseases caused by pneumococcus.

After learning about the relevant introduction of pneumococcal vaccine, although it is very harmful to get vaccinated, I would like to advise friends with allergies not to get vaccinated. In addition, pneumococcal vaccine is not recommended for children with impaired cardiopulmonary function. I hope parents can pay attention to these special circumstances.